It was demonstrated through clinical trials that combining alpha-1 blockers that are commonly used for the treatment of BPH, such as alfuzosin with PDE5 inhibitors, tadalafil or sildenafil, helps relieve the sexual and urinary symptomps in patients with BPH, or those suffering from both BPH and ED [67]. Here, PDE5A is linked to benign prostatic hyperplasia.